Articles tagged with Alzheimer Disease
A new study has found that patients with mild or no cognitive impairment can be identified as at risk of developing Alzheimer's disease through a PET brain scan using a radioactive dye. The study, led by researchers at Duke University Medical Center, shows that the presence of amyloid plaques in the brain can predict future decline.
Researchers at Washington University School of Medicine have developed the most detailed chronology to date of the human brain's slow slide into full-blown Alzheimer's disease. The timeline reveals changes in brain structure and function decades before symptoms of memory loss and cognitive decline appear.
Research finds that people at risk for early-onset Alzheimer's disease want to know their genetic profile, but struggle with the results. The study also reveals that the general population and those with a family history of late-onset AD tend to be motivated by fear and anxiety when considering genetic testing.
A clinical trial found that Souvenaid improved verbal-memory performance in 40% of patients with mild Alzheimer's, while a control group showed deterioration. The nutrient cocktail boosts new synapse formation, potentially reversing cognitive decline.
Researchers at UCSB used computer simulations to understand the formation of toxic entities in the brain, finding that small oligomer molecules may be responsible for the onset of the disease. These findings suggest new diagnostic and treatment options, including peptide-based inhibitors.
Researchers found that chronic inflammation caused by immune system challenges can lead to long-term neurological changes and memory problems in mice. The study suggests that this early event may be an important step in the development of Alzheimer's disease.
A genome-wide association study identified several genes associated with hippocampal atrophy, a key feature of Alzheimer's disease. The study found novel associations between brain degeneration and genes in the APOE, F5/SELP, LHFP, and GCFC2 gene regions.
A recent study published in Journal of Biological Chemistry suggests that exercise is more beneficial than diet control in reducing β-amyloid formation and restoring memory loss associated with Alzheimer's disease. The research found that exercise alone can significantly reduce the risk of developing the disease.
A study by Rhode Island Hospital researcher Suzanne de la Monte found a significant link between brain insulin resistance and neuronal stress in the progression of Alzheimer's disease. The research suggests that reducing toxin production in the brain and restoring insulin responsiveness may help slow cognitive decline.
A new research project investigates the link between chronic stress and Alzheimer's disease development. The study aims to understand how stress may become a risk factor for developing dementia, with the goal of finding ways to intervene with psychological or drug-based treatments.
Researchers found significant improvements in memory and thinking among cancer patients treated with GMCSF plus GCSF compared to those receiving GCSF alone. The study suggests that GMCSF may prevent or reverse cognitive decline in cancer patients, in addition to Alzheimer's patients.
A new study confirms that hospitalization and delirium in Alzheimer's patients lead to hastened cognitive decline, institutionalization, and death. Effective prevention strategies such as the Hospital Elder Life Program can mitigate this risk.
The Collaborative Research Awards Program in Alzheimer's Disease will support interdisciplinary basic and translational research projects. This program aims to spur creative approaches that advance the care of those with Alzheimer's disease by fostering collaboration across disciplines.
Researchers at the Peninsula College of Medicine and Dentistry have identified a key player in the immune system that may protect against Alzheimer's changes. The CCR2 gene was found to be associated with memory in people, suggesting that strengthening this part of the immune system could slow the disease.
Researchers at CCNY found that a single gene forms a common link between diabetes and Alzheimer's disease, affecting the insulin pathway. The finding could point to a therapeutic target for both diseases.
A new study published in Genetics reveals a gene in Caenorhabditis elegans, similar to a human gene correlated with Alzheimer's disease, is involved in multiple metabolic pathways, including insulin. The discovery suggests that this gene plays a role not only in Alzheimer's but also in diabetes.
Researchers at Boston University School of Medicine have identified a new group of RNA-binding proteins that accumulate in the brains of patients with Alzheimer's disease. These findings may lead to novel diagnostic approaches and a better understanding of the disease progression.
Researchers found that ApoE4 gene variant affects brain function in healthy older women, causing changes characteristic of Alzheimer's disease, but has little impact on men. The study suggests a gender distinction in Alzheimer's risk, with implications for risk assessment and experimental avenues for understanding the disease.
Researchers have made significant breakthroughs in Alzheimer's disease detection using molecular imaging technology, which can identify beta-amyloid plaques in the brain. Studies show that high levels of amyloid binding are associated with an 80% chance of developing Alzheimer's disease within two years.
Piramal Imaging will present data from five florbetaben studies, including a pivotal Phase III trial that will provide the basis for regulatory submission later this year. The company is developing an innovative and proprietary tracer portfolio to address major clinical needs in Alzheimer's disease and other conditions.
Researchers at Mayo Clinic identified altered gene expression levels in over 2,000 genes associated with neurodegenerative diseases. These genetic variants contribute to disease development and progression, providing potential targets for new therapies.
Researchers at Karolinska Institutet report positive effects of an active vaccine, CAD106, against Alzheimer's disease. The study found that 80% of patients developed protective antibodies without side effects.
A recent study found that moderate coffee consumption can appreciably reduce the risk of Alzheimer's disease and delay its onset. Higher blood caffeine levels were associated with a reduced risk of dementia or delayed onset, suggesting that coffee may be a protective factor against Alzheimer's.
Researchers at Universitat Autonoma de Barcelona have developed a new multitarget molecule, ASS234, which inhibits ß-amyloid protein aggregation, stimulates cholinergic and monoaminergic transmission, and crosses the blood-brain barrier. This molecule has shown promising therapeutic effects in patients with Alzheimer's disease.
Researchers at Vanderbilt University discovered a new therapeutic strategy to reduce amyloid-beta production in Alzheimer's disease. By understanding how cholesterol binds to the amyloid precursor protein, they found that blocking this interaction could prevent amyloid-beta generation and treatment of dementia.
Researchers found that a specific gene, CCR2, associated with immune activity is linked to memory and cognitive function in people. This discovery could lead to new approaches to slowing or preventing Alzheimer's disease.
Researchers discovered that astrocytes, which normally nourish and protect neurons, deliver a lethal package containing ceramide and PAR-4 when neurons start producing excessive amyloid protein. This process may contribute to brain-cell death and shrinkage in Alzheimer's disease.
Researchers found that a genetic risk factor for Alzheimer's disease triggers a cascade of signaling that leads to leaky blood vessels and toxic substance entry into brain tissue. Blocking cyclophilin A or using the drug cyclosporine A reversed damage in mice, restoring blood flow and reducing toxic substance leakage.
A new study funded by the NIH found that the ApoE4 gene variant damages blood vessels in the brain, leading to increased risk of Alzheimer's disease. The researchers discovered that ApoE4 triggers an inflammatory reaction that weakens the blood-brain barrier, allowing harmful substances to enter the brain.
The MetLife Foundation Awards for Medical Research in Alzheimer's Disease recognize novel approaches to understanding and treating the disease. The winners, Dr. Clifford Jack Jr., Dr. Christine Van Broeckhoven, and Dr. Randall Bateman, have made significant discoveries that clarify our understanding of Alzheimer's disease.
A national phase II clinical trial will examine the effects of resveratrol on individuals with mild to moderate dementia due to Alzheimer's disease. The study aims to delay or alter memory deterioration and daily functioning in people with the condition.
A study published in Neuron suggests that reducing excess brain activity may improve memory and interrupt disease progression in patients with cognitive impairment, a potential new therapeutic approach for Alzheimer's disease. The findings are consistent with research in animal models and suggest that elevated hippocampal activation co...
Researchers found that reducing hippocampal activity improved performance on a memory task in patients with amnestic mild cognitive impairment. Elevated activity in this brain region is often seen in disorders associated with an increased risk for Alzheimer's disease.
A small phase I study suggests that deep brain stimulation, a therapy used for Parkinson's and depression, may increase neuronal activity in people with mild Alzheimer's disease. The treatment showed promising effects on brain function, including sustained increases in glucose metabolism.
A new study found that people who reported greater purpose in life exhibited better cognition than those with less purpose, even as plaques and tangles accumulated. This suggests that engaging in meaningful activities promotes cognitive health in old age.
A study of 13,535 individuals found that depressive symptoms in midlife and late life are associated with a higher risk of developing dementia. Those with chronic depression during their lifetime had a two-fold increase in Alzheimer's disease risk, while those with depression in both midlife and late life had a three-fold increase in v...
Researchers have discovered a new, non-invasive diagnostic method for Alzheimer's disease (AD) using advanced brain imaging technology. The technique analyzes specific brain chemical changes in the hippocampal region of the brain, providing a signature of early AD stages.
A new study suggests that consuming omega-3 fatty acids from foods like fish and nuts can lower blood beta-amyloid levels, a protein linked to Alzheimer's disease. The study found a strong association between increased omega-3 intake and reduced plasma beta-amyloid levels.
A new randomized controlled trial found that memantine, a commonly prescribed medication for Alzheimer's disease, is no more effective in reducing significant agitation than a placebo. The study suggested improvements in cognitive functioning and neuropsychiatric symptoms, but failed to provide relief from severe agitation.
Researchers at Mount Sinai School of Medicine have developed a biosynthetic polyphenol that improves cognitive function in mice with Alzheimer's disease. The compound reduces brain neuropathology by preventing abnormal protein accumulation, promoting plasticity and benefits in learning and memory functions.
Researchers discover that a highly toxic beta-amyloid protein triggers Alzheimer's disease by converting abundant beta-amyloids into a more toxic form. This process involves the interaction of beta-amyloid with tau protein, leading to the formation of toxic tangles in the brain.
A research group led by Giulio Maria Pasinetti has discovered that misfolded tau released by neurons can spread to surrounding cells, promoting the progression of neurodegenerative disorders. A grape-seed extract enriched in polyphenols was also found to prevent cell-to-cell spread of tau pathology.
UC Davis researchers have discovered novel compounds that disrupt amyloid formation and reduce inflammation in neurons, potentially preventing or delaying Alzheimer's disease damage. The spin-labeled fluorene compounds demonstrate excellent detection of amyloid and anti-inflammatory properties.
Researchers found that low Nav1.1 levels disrupt brain cell electrical activity, leading to memory problems and cognitive decline. Restoring Nav1.1 levels improves learning, memory functions, and lifespan in AD-mice.
Researchers found a significant relationship between decreased CSF αβ 1-42 and clinical decline in participants with elevated CSF p-tau 181p, suggesting p-tau as an important marker of AD-associated degeneration. The study suggests that targeting tau may be crucial for therapy development.
A new study reveals that both amyloid-beta plaque deposits and elevated levels of the altered protein p-tau are required for clinical decline in Alzheimer's disease. The presence of both is associated with significant clinical decline over three years, highlighting p-tau as a potential target for new therapies.
Recent studies suggest that prolonged administration of human immunoglobulin can attenuate Alzheimer's disease-type cognitive dysfunction while promoting synaptic plasticity. This experimental observation provides a rational basis for rectifying inconsistent study outcomes in Alzheimer's disease clinical trials with IVIG.
A study published in Nature Communications reveals the progressive decline of function in cortical circuits due to Alzheimer's disease. Researchers observed correlations between beta-amyloid increases and dysfunctional developments in individual neurons, neuronal circuits, sensory cognition, and behavior.
A team of researchers from the University of Pennsylvania School of Medicine has demonstrated that a range of diagnostic spinal fluid tests are needed to differentiate between brain diseases such as Alzheimer's disease and frontotemporal lobar degeneration. The studies found that biomarkers in cerebrospinal fluid, including tau and amy...
A study published in Neurology found that daily physical exercise and low-intensity activities like cooking and washing dishes can reduce the risk of Alzheimer's disease. People in the bottom 10% of daily activity were more than twice as likely to develop Alzheimer's, highlighting the importance of regular movement.
A new study by Rush University Medical Center found that daily physical activity is associated with a reduced risk of Alzheimer's disease and cognitive decline. The study, which tracked the activities of 716 older individuals over 3.5 years, showed that those in the bottom 10% of daily physical activity were more than twice as likely t...
Scientists discovered the Nurr1 gene plays a crucial role in neuron survival associated with synaptic activity. The findings provide insight into the relationship between early synaptic deficits and neurodegeneration in Alzheimer's disease.
Researchers have identified genetic mutations linked to hippocampal shrinkage, a recognized biological marker of Alzheimer's disease. The study found that these mutations affect genes involved in cell death, embryonic development, and neuronal migration.
Researchers at BUSM identified four genetic loci associated with decreased hippocampal volume, a trait linked to Alzheimer's disease and aging. The findings suggest that specific genes may influence cell death, brain development, and memory performance.
A large international study has found that certain versions of four genes may speed up the shrinkage of the hippocampus, a brain region involved in making new memories. The research suggests that these gene variants may increase vulnerability to Alzheimer's disease by accelerating hippocampus shrinkage.
A new method using florbetaben PET scans may help diagnose Alzheimer's disease earlier by detecting beta-amyloid plaques in the brain. The study found a sensitivity of 77% and specificity of 94% compared to post-mortem diagnosis, with even higher accuracy for visual assessments.
A study of over 21,000 participants found new genes that boost or lessen the risk of brain atrophy, mental illness, and Alzheimer's disease. The research also uncovered genetic variants associated with individual differences in brain size and intelligence.
A study published in Nature Communications found that sAPP-α, a secreted portion of APP, acts as an essential stop-gap mechanism to regulate APP production. Monitoring and correcting low sAPP-α levels or enhancing its association with BACE1 may help prevent or treat Alzheimer's disease.
A new study by Brown University researchers reveals that Medicare spends significantly more on hospitalizations before patients enter a nursing home, with an average cost of $29,743 per patient. Once the patient becomes a permanent resident, costs drop to under $19,000. The study suggests that reducing hospitalizations before nursing h...
A new MRI technique uses computer modeling to predict the rate and physical path of degenerative brain diseases like Alzheimer's and frontotemporal dementia. The study supports the idea that these diseases spread through the brain along specific neuronal pathways, similar to prion diseases.